阿托伐他汀联合尼莫地平治疗蛛网膜下腔出血的临床疗效及对血清S-100B、Ang水平的影响

目的:探讨阿托伐他汀联合尼莫地平治疗蛛网膜下腔出血的临床疗效及对患者血清蛋白(S-100B)、血管生成素(Ang)水平的影响。方法:选择2015年1月至2016年1月我院收治的蛛网膜下腔出血患者90例,采用随机数表法分为观察组(n=45)和对照组(n=45)。观察组采用阿托伐他汀联合尼莫地平进行治疗,对照组采用尼莫地平治疗。比较两组患者的临床疗效及治疗前后脑动脉平均血流速度、美国国立卫生研究院卒中量表(NIHSS)、日常生活能力量表(BI)、血清S-100B、人血管生成素(ANG)水平的变化及不良反应的发生情况。结果:治疗后,观察组总有效率为93.33%,显著高于对照组(73.33%,P0.05)。治疗后,两组患者脑动脉平均血流速度、NIHSS及BI评分均较治疗前明显改善,且观察组患者脑动脉平均血流速度、BI评分均高于对照组;NIHSS评分明显低于对照组(P0.05);治疗后,两组血清S-100B、ANG水平较治疗前均显著降低(P0.05),且观察组血清S-100B、ANG水平均明显低于对照组(P0.05)。观察组并发症发生率为13.33%,明显低于对照组(46.67%,P0.05)。结论:阿托伐他汀联合尼莫地平治疗蛛网膜下腔出血患者的疗效及安全性均明显优于单用尼莫地平治疗治疗,可能与其有效降低血清S-100B、ANG水平有关。

Curative Efficacy of Atorvastatin Combined with Nimodipinein in the Treatment of Subarachnoid Hemorrhage and Its Effects on the Serum s-100b and Ang Levels

ABSTRACT Objective: To study the efficacy of Atorvastatin combined with nimodipine in the treatment of Subarachnoid hemorrhage and its effects on the serum Protein (s-100b), angiopoietin (Ang) levels. Methods: 90 patients with subarachnoid hemorrhage admitted to our hospital from January 2015 to January 2016 were selected and divided into the observation group (n=45) and the control group (n=45) by the random number table method. The observation group was treated with atorvastatin combined with nimodipine, while the control group was treated with nimodipine. The clinical efficacy, changes of mean cerebral artery blood flow velocity, national institutes of health stroke scale (NIHSS), daily living ability scale (BI), serum s-100, and human angiopoietin (ANG) levels and the incidence of adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of observation group was 93.33%, which was significantly higher than that of the control group (73.33%, P<0.05). After treatment, the mean cerebral artery blood flow velocity, NIHSS and BI scores of patients in both groups were significantly improved compared with those before treatment, and the mean cerebral artery blood flow velocity and BI scores of patients in the observation group were higher than those in the control group. The NIHSS score was significantly lower than that of the control group (P<0.05). After treatment, the serum s-100 and ANG levels in both groups were significantly lower than those before treatment (P<0.05), and serum s-100 and ANG levels in the observation group were significantly lower than those in the control group (P<0.05). The incidence of complications in the observation group was 13.33%, which was significantly lower than that in the control group (46.67%, P<0.05). Conclusion: The efficacy and safety of atorvastatin combined with nimodipine in the treatment of patients with subarachnoid hemorrhage are significantly better than that of nimodipine alone, which may be related to its effective reduction of serum s-100 and ANG levels.